BEIJING: Authorities in Peru and Morocco have approved phase three clinical trials for a potential Covid-19 vaccine developed by China National Biotec Group (CNBG), the company said late on Thursday on Chinese social media platform WeChat.
Phase three trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has entered a phase three trial in the United Arab Emirates that has already recruited 15,000 volunteers.
It has also obtained approval to be tested in Bahrain in a phase three study designed to involve around 6,000 participants.